We develop therapeutics to protect your gut from cancer therapy
Radiation and chemotherapy have side effects that kill gut epithelial cells and tear apart the protective gut barrier. These oncology treatments start a damaging cycle that causes inflammation, infection, and may lead to sepsis and death. This injury is called GI mucositis.
Patients with GI mucositis may experience symptoms that include inability to swallow, diarrhea, ulcerations of the GI tract, bleeding, stool incontinence, or in severe cases, tissue necrosis. GI mucositis is the single most important dose limiting factor in cancer therapy. Many patients will go on to experience GI mucositis symptoms long after their therapy has ended. GI mucositis has no treatment options.
SYGN305: protection for your gut against cancer therapy
Synedgen is developing first-in-class cancer supportive therapeutics to repair GI mucositis injury, promote healing, and restore a healthy microbiome. Our lead drug, SYGN305, is being developed to help patients tolerate cancer therapy by managing acute GI side effects and preventing lasting damage to the GI tract. SEE SYGN305
March 3, 2020
Synedgen Announces $1 Million Award from Defense Health Agency to Develop SynePure and Catasyn
February 18, 2020
Synedgen To Present Data on Therapeutic for Ocular Mustard Gas Injury at NIH-Organized Medical Countermeasures Meeting
January 29, 2020
Synedgen Receives $2.6 Million in Private Financing For Wound Care Portfolio